Canada · Delayed Price · Currency is CAD TelyRx Holdings Statistics
Total Valuation
TelyRx Holdings has a market cap or net worth of CAD 127.01 million. The enterprise value is 115.38 million.
| Market Cap | 127.01M |
| Enterprise Value | 115.38M |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TelyRx Holdings has 48.85 million shares outstanding. The number of shares has increased by 168.46% in one year.
| Current Share Class | 26.35M |
| Shares Outstanding | 48.85M |
| Shares Change (YoY) | +168.46% |
| Shares Change (QoQ) | +333.56% |
| Owned by Insiders (%) | 8.55% |
| Owned by Institutions (%) | n/a |
| Float | 26.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.30 |
| PB Ratio | 8.20 |
| P/TBV Ratio | 9.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.46, with a Debt / Equity ratio of 1.24.
| Current Ratio | 3.46 |
| Quick Ratio | 3.03 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.00 |
| Interest Coverage | -17.93 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -51.44% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TelyRx Holdings has paid 25,562 in taxes.
| Income Tax | 25,562 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.56 |
| Average Volume (20 Days) | 11,766 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TelyRx Holdings had revenue of CAD 97.58 million and -18.89 million in losses. Loss per share was -0.92.
| Revenue | 97.58M |
| Gross Profit | 54.62M |
| Operating Income | -17.16M |
| Pretax Income | -18.86M |
| Net Income | -18.89M |
| EBITDA | -17.34M |
| EBIT | -17.16M |
| Loss Per Share | -0.92 |
Balance Sheet
The company has 30.78 million in cash and 19.15 million in debt, with a net cash position of 11.63 million or 0.24 per share.
| Cash & Cash Equivalents | 30.78M |
| Total Debt | 19.15M |
| Net Cash | 11.63M |
| Net Cash Per Share | 0.24 |
| Equity (Book Value) | 15.49M |
| Book Value Per Share | 0.32 |
| Working Capital | 25.75M |
Cash Flow
In the last 12 months, operating cash flow was -8.83 million and capital expenditures -765,434, giving a free cash flow of -9.59 million.
| Operating Cash Flow | -8.83M |
| Capital Expenditures | -765,434 |
| Depreciation & Amortization | -173,469 |
| Net Borrowing | 3.86M |
| Free Cash Flow | -9.59M |
| FCF Per Share | -0.20 |
Margins
Gross margin is 55.97%, with operating and profit margins of -17.59% and -19.36%.
| Gross Margin | 55.97% |
| Operating Margin | -17.59% |
| Pretax Margin | -19.33% |
| Profit Margin | -19.36% |
| EBITDA Margin | -17.77% |
| EBIT Margin | -17.59% |
| FCF Margin | n/a |
Dividends & Yields
TelyRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -168.46% |
| Shareholder Yield | -168.46% |
| Earnings Yield | -14.87% |
| FCF Yield | -7.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 7, 2026. It was a reverse split with a ratio of 0.0333333.
| Last Split Date | Apr 7, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.0333333 |
Scores
TelyRx Holdings has an Altman Z-Score of 3 and a Piotroski F-Score of 3.
| Altman Z-Score | 3 |
| Piotroski F-Score | 3 |